← Back to Screener
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Price$6.76
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-14.30%
Price vs S&P 500 (4W)-12.31%
VGM Score65.35
Market Capitalization$413.61M
All Metrics
Book Value / Share (Quarterly)$3.14
P/TBV (Annual)3.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.22
Price vs S&P 500 (YTD)6.03%
EPS (TTM)$-1.34
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$-1.34
EPS (Annual)$-1.58
ROI (Annual)-45.82%
Cash / Share (Quarterly)$3.21
ROA (Last FY)-43.82%
EBITD / Share (TTM)$-1.50
ROE (5Y Avg)-51.85%
Cash Flow / Share (Annual)$-1.40
P/B Ratio4.04x
P/B Ratio (Quarterly)1.66x
Net Income / Employee (Annual)$-3,189,900
ROA (TTM)-35.52%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)22.82x
Quick Ratio (Quarterly)19.86x
3-Month Avg Trading Volume1.23M
52-Week Price Return41.42%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.27
P/S Ratio (Annual)206.80x
Asset Turnover (Annual)0.02x
52-Week High$11.41
EPS Excl Extra (Annual)$-1.58
26-Week Price Return-6.37%
Quick Ratio (Annual)22.27x
13-Week Price Return24.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.34x
Enterprise Value$376.98M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1393.80%
Cash / Share (Annual)$3.48
3-Month Return Std Dev107.76%
Net Income / Employee (TTM)$-2,719,500
ROE (Last FY)-45.82%
EPS Basic Excl Extra (Annual)$-1.58
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.34
ROI (TTM)-37.57%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.28
Price vs S&P 500 (52W)17.06%
Year-to-Date Return14.19%
5-Day Price Return-5.98%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-46.96%
Net Profit Margin (Annual)-1393.80%
Month-to-Date Return-7.27%
EBITD / Share (Annual)$-1.76
Operating Margin (Annual)-1537.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.85%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.34
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)1.65x
Book Value / Share (Annual)$3.42
Price vs S&P 500 (13W)15.78%
Beta3.47x
Revenue / Share (TTM)$0.00
ROE (TTM)-37.57%
52-Week Low$4.00
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.33est. -0.38
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SGMTSagimet Biosciences Inc. Series A Common Stock | — | — | B | $6.76 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat metabolic diseases driven by dysfunctional lipid metabolism. The company's lead candidate, denifanstat, is an oral, once-daily FASN inhibitor in development for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated liver disease. Sagimet is focused on advancing its proprietary FASN inhibitor platform across multiple indications where lipid dysregulation plays a pathogenic role.